Date de début : 15.08.2024
Responsable : NANCHEN David
Groupe de recherche : Prévention cardiovasculaire
Financeur :
- Swiss Atherosclerosis Association
Statins are prescribed to lower low-density lipoprotein cholesterol (LDL-C), which in turn reduces atherosclerotic cardiovascular disease (ASCVD).
However, evidence suggests statin prescription has a dose-dependent impact on the incidence of diabetes mellitus (DM).
Epigenetic modifications have the potential to reflect the impact of statin therapy on a molecular level and may provide a tool for identifying individuals at risk for developing DM in the prodromal phase.
The objective of this project is therefore to investigate the mechanistic actions of statins on diabetes-associated biomarkers by way of epigenetics.